Skip to main content

Table 2 Cohort size, person years and incident cases of breast cancer subtypes across five-year age bands.

From: Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study

 

Age bands

 

≤ 49 years

50-54 years

55-59 years

60-64 years

≥ 65 years

All women

Subjects at risk

141513

175268

185404

161850

113810

314670

Person years

870491

627875

661652

565289

673872

3399178

Total cases 1

1205

(12.6%)

1770

(18.6%)

2151

(22.6%)

2065

(21.7%)

2339

(24.5%)

9530

ER-positive

507

(8.8%)

1031

(17.9%)

1402

(24.3%)

1345

(23.3%)

1479

(25.7%)

5764

ER-negative

235

(16.7%)

306

(21.7%)

320

(22.7%)

294

(20.9%)

255

(18.1%)

1410

ER-missing

463

(19.7%)

433

(18.4%)

429

(18.2%)

426

(18.1%)

605

(25.7%)

2356

PR-positive

462

(12.1%)

755

(19.8%)

872

(22.9%)

839

(22.0%)

880

(23.1%)

3808

PR-negative

212

(10.0%)

397

(18.8%)

553

(26.2%)

499

(23.6%)

453

(21.4%)

2114

PR-missing

531

(14.7%)

618

(17.1%)

726

(20.1%)

727

(20.1%)

1,006

(27.9%)

3608

ER+PR+

390

(10.9%)

698

(19.5%)

830

(23.1%)

806

(22.5%)

862

(24.0%)

3586

ER+PR-

64

(5.9%)

180

(16.6%)

306

(28.2%)

280

(25.8%)

256

(23.6%)

1086

ER-PR+

71

(33.3%)

57

(26.8%)

37

(17.4%)

31

(14.6%)

17

(8.0%)

213

ER-PR-

147

(14.4%)

217

(21.3%)

244

(23.9%)

217

(21.3%)

196

(19.2%)

1021

ER or PR missing

533

(14.7%)

618

(17.1%)

734

20.3%

731

(20.2%)

1008

(27.8%)

3624

  1. 1Including women of unknown receptor status. ER, estrogen receptor; PR, progesterone receptor.